Pinned
New email, who dis?
I've officially landed at @statnews to cover biopharma startups and venture capital. Send tips/questions to [email protected].
Allison DeAngelis
5,383 posts
Allison DeAngelis
@ADeAngelis_bio
Reporter covering biopharma startups and venture capital at @statnews. Formerly @thisisinsider and @bosbizjournal.
Joined February 2011
- *Some personal news* Today was my last day at Insider. Starting later this month, I'm going to be covering biopharma startups and VC for @statnews.
- Scoop: MIT scientist David Sabatini has been placed on administrative leave after an outside investigation into misconduct in his lab.
- Advice to PR people: It is bad form to pitch news under general embargo, then revoke that offer in order to give one outlet an "exclusive".
- PSA to biotech founders/execs/PR folks: If you're putting out press releases, it's ludicrous to insist you're still in "stealth mode."
- Over the past couple of months, I’ve spoken to 5 biotech founders who were asked to give up control of their startups while raising their seed rounds. Several turned to tech VCs, who they find more open to founder-CEOs and willing to take less equity.
- Many months ago, STAT got a tip about a data issue at a new RNA medicines company. The company, Laronde, had raised nearly $500 million on the promise of "endless" RNA, a new technology that could last longer and be more applicable than messenger RNA.
- One pro of #JPM22 being virtual: I made a damn good penne alla vodka while listening to an investor presentation today.
- Merck is acquiring startup Caraway Therapeutics, which is developing drugs for neurodegenerative disorders. The pharma co will pay up to $610 million. Caraway raised a $23 million Series A round in 2018 and has basically lived off of that cash since.
- You know you’re in Cambridge when you find a Moderna T shirt at the thrift $MRNA
